Editorial

As we embark on the first issue of volume 3 of *Prostate Cancer and Prostatic Diseases* we are pleased to note that the Journal has been listed in Current Contents since the second issue of volume 2, a substantial achievement for such a young journal. We plan to apply for listing in Index Medicus early next year. We therefore encourage you to continue to send in your very best original papers and reviews so that we can maintain the high standard achieved in volumes 1 and 2 of this journal.

We hope you agree that there is much to interest and stimulate all those interested in prostatic diseases in this current issue. In the Hot News section Arie Belldgrun reports from the very recent European Association of Urology meeting in Brussels. In our review section Cooper et al look at the mechanisms of cell adhesion and chemotaxis in bone metastases, while Mahapokai and colleagues consider models for the study of benign prostatic hyperplasia (BPH). Durkan and Greene review the diagnostic dilemmas associated with the detection of prostate cancer in men undergoing transrectal ultrasono-

graphy and Don Newling discusses the latest concepts associated with progression of hormonal therapy in patients with advanced prostate cancer.

Clinical issues surrounding the diagnosis and treatment of prostatic disease are always central in this journal and among the original papers is a report from Adolfsson on the outcome after 30 years of localised prostate cancer treated by watchful waiting. Bauer et al report an increased detection rate of cancer when lateral biopsies are added to the traditional sextant approach. Feneley and coworkers have evaluated prostate specific membrane antigen (PSMA) as a novel means of imaging prostate cancer. Histopathology also features prominently in this issue: Yorukoglu discusses the importance of ganglion cells in the human prostate and Helal *et al* report several cases of adenosquamous carcinoma of the prostate following irradiation.

R Kirby, H Scher and M Brawer